Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
-
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional...
-
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
-
DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection ...
-
Novel immuno-oncology algorithm may offer independent and incremental predictive value over current standard biomarkers in the clinic Data suggest that measuring the tumor microenvironment (TME) as a...
-
-Results achieved in metastatic bladder cancer suggests Oncocyte’s DetermaIO test may be a strong predictor of Immune Checkpoint Inhibitor (ICI) therapy response in a third cancer type in addition to...
-
IRVINE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
-
IRVINE, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
-
IRVINE, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
-
IRVINE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...